These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2877572)

  • 1. Pharmacodynamics of famotidine in humans.
    Chremos AN
    Am J Med; 1986 Oct; 81(4B):3-7. PubMed ID: 2877572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of famotidine: a summary.
    Chremos AN
    J Clin Gastroenterol; 1987; 9 Suppl 2():7-12. PubMed ID: 2887616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs.
    Yuki H; Kamato T; Nishida A; Fujihara A; Takeda M; Miyata K
    Jpn J Pharmacol; 1993 Nov; 63(3):345-51. PubMed ID: 7906319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
    Scarpignato C; Tramacere R; Zappia L
    Br J Pharmacol; 1987 Sep; 92(1):153-9. PubMed ID: 2889492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of famotidine.
    Smith JL
    Digestion; 1985; 32 Suppl 1():15-23. PubMed ID: 2866132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.
    Ryan JR; Chremos AN; Vargas R; Mantell G; Johnson CL; McMahon FG
    Clin Pharmacol Ther; 1987 Aug; 42(2):225-31. PubMed ID: 2886245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
    Reeves JJ; Stables R
    Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion.
    Ryan JR; Vargas R; McMahon FG; Chremos AN
    Am J Med; 1986 Oct; 81(4B):60-4. PubMed ID: 2877576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric antisecretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs.
    Shibata M; Yamaura T; Inaba N; Onodera S; Chida Y; Ohnishi H
    Eur J Pharmacol; 1993 Apr; 235(2-3):245-53. PubMed ID: 8099553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of the novel H2 antagonist famotidine: in vitro studies.
    Bertaccini G; Coruzzi G; Poli E; Adami M
    Agents Actions; 1986 Nov; 19(3-4):180-7. PubMed ID: 2881455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a histamine H2-receptor antagonist, famotidine, on gastric secretion in healthy subjects.
    Fukuda Y; Ikezoe I; Okabayashi M; Ohama I; Shimoyama T
    Clin Ther; 1987; 9(5):528-35. PubMed ID: 2889528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of ranitidine, famotidine and omeprazole on plasma gastrin in the rat.
    Decktor DL; Pendleton RG; Kellner AT; Davis MA
    J Pharmacol Exp Ther; 1989 Apr; 249(1):1-5. PubMed ID: 2565384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of H2-receptor antagonists upon physiological acid secretory states in animals.
    Pendleton RG; Cook PG; Shepherd-Rose A; Mangel AW
    J Pharmacol Exp Ther; 1985 Apr; 233(1):64-9. PubMed ID: 2858583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man.
    Smith JL; Gamal MA; Chremos AN; Graham DY
    Dig Dis Sci; 1985 Apr; 30(4):308-12. PubMed ID: 2858363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogs.
    Takeda M; Takagi T; Maeno H
    Eur J Pharmacol; 1983 Aug; 91(4):371-6. PubMed ID: 6137398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a new potent H2-blocker, 3-]]]2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs.
    Takagi T; Takeda M; Maeno H
    Arch Int Pharmacodyn Ther; 1982 Mar; 256(1):49-58. PubMed ID: 6124219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of famotidine on renal function in patients with renal insufficiency.
    Abraham PA; Opsahl JA; Halstenson CE; Chremos AN; Matzke GR; Keane WF
    Br J Clin Pharmacol; 1987 Sep; 24(3):385-9. PubMed ID: 2889461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological analysis of the CCKB/gastrin receptors mediating pentagastrin-stimulated gastric acid secretion in the isolated stomach of the immature rat.
    Hills DM; Gerskowitch VP; Roberts SP; Welsh NJ; Shankley NP; Black JW
    Br J Pharmacol; 1996 Dec; 119(7):1401-10. PubMed ID: 8968549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.